Mary Kelley
Professor
Research Professor
Faculty, Biostatistics and Bioinformatics
Dr. Kelley has worked with the Emory Psychiatry department studying the biological predictors (imaging, genetics, immune) of treatment response in depression. She is well-versed in the challenges of research involving complex behavioral assessments and evaluation of interventions in behaviorally disordered patients, and has an extensive background in statistical analysis relevant to studies of human behavior including clinical trials of psychopharmacological therapies, scale/survey development and evaluation, and imaging applications in psychiatric research. In addition to the studies in depression treatment, she is currently involved in a study of the effects of substance use and early life events in first episode schizophrenia patients, as well as a trial of a new outpatient treatment for the severely mentally ill (SMI) with this diagnosis. Dr. Kelley also has extensive experience in health services research having worked for at the Center for Health Equity and Research Promotion (CHERP - VA Pittsburgh) for 6 years. At that time, she was involved in a number of studies on subjects with CHD including assessment of treatment practices, the effects of alcohol use, and predictive risk models for cardiovascular outcomes. She most recently has re-entered health services research as the Director of Biostatistics for the Division of Informatics and Health Services Research in the Department of Anesthesiology, School of Medicine. These studies are currently focused on predictive models for short term mortality in ICU patients, using high fidelity minute to minute data from TeleICU. Her methodology work evolves from her extensive experience with categorical (primarily ordinal) data, and is focused on the issues of non-response evident in many behavioral scales that result in “zero inflation”, use of ordinal data in the development of latent constructs, and assessment of longitudinal response.
Contact Information
Rollins School of Public Health , 1518 Clifton Road NE
Atlanta , GA 30322
Phone: (404) 712-0804
Fax: (404) 727-1370
Email: mekelle@emory.edu
Areas of Interest
- Imaging
- Mental Health
- Statistical Modeling
Education
- Ph.D. 2003, University of Pittsburgh Grad Sch of Public Health
- M.S. 1995, University of Pittsburgh, Grad Sch of Public Health
- B.S. 1988, University of Pittsburgh
Courses Taught
- BIOS 726: Applied Multivariate Analysis
- BIOS 732: Advanced Numerical Methods
Affiliations & Activities
Statistical Editor, JAMA Psychiatry
Publications
- Kelley ME, Choi KS, Rajendra JK, Craighead WE, Rakofsky JJ, Dunlop BW, Mayberg HS., 2021, Establishing evidence for clinical utility of a neuroimaging biomarker in major depressive disorder: Prospective testing and implementation challenges, Biol Psychiatry, in press,
- Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carillo-Roa T, Binder EB, Kutner MH, Aponte Rivera V, Craighead WE, Mayberg HS, 2018, Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse, Depression and Anxiety, 35, 992-1000
- Dunlop BW, Rajendra JK, Craighead WE, Kelley ME, McGrath CL, Choi KS, Kinkead B, Nemeroff CB, Mayberg HS, 2017, Functional connectivity of the subcallosal cingulate cortex and outcomes to treatment with cognitive behavior therapy and antidepressant medication for major depressive disorder, Am J Psychiatry, 174, 533-545
- Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF, Compton MT, 2016, Marijuana use in the immediate 5-year period is associated with increased risk of onset of schizophrenia and related psychotic disorders., Schizophr Res, 171, 62-67
- Kelley ME, White L, Compton MT, Harvey PD, 2013, Subscale structure for the Positive and Negative Syndrome Scale (PANSS): A proposed solution focused on clinical validity. , Psychiatry Research, 205, 137-142
- McGrath CL, Kelley ME, Holtzheimer III PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS, 2013, Toward a neuroimaging treatment selection biomarker for major depressive disorder., JAMA Psychiatry, ,
- Holtzheimer III PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A, Wint D, Craighead MC, Kozarsky J, Chismar R, Moreines JL, Mewes K, Riva Posse P, Gutman DA, Mayberg HS, 2012, Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression, Arch Gen Psychiatry, 69(2), 150-8
- Kelley ME, Franco AR, Mayberg HS, Holtzheimer III, PE, 2012, The Illness Density Index (IDI): A longitudinal measure of treatment efficacy., Clinical Trials, 9, 596-604
- Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF., 2009, Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients, Am J Psychiatry, 166, 1251-1257
- Kelley ME, Haas GL, van Kammen, DP., 2008, Longitudinal progression of negative symptoms in schizphrenia: A new look at an old problem., Schizophr Res, 105, 188-196
- Kelley ME, Anderson SJ., 2008, Zero inflation in ordinal data: Incorporating susceptibility of response through the use of a mixture model., Statistics in Medicine, 27, 3674-3688